<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathogenesis of autoimmune adrenal insufficiency
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathogenesis of autoimmune adrenal insufficiency
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathogenesis of autoimmune adrenal insufficiency
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common cause of primary adrenal insufficiency is autoimmune adrenalitis. This topic will review the pathogenesis of autoimmune adrenal insufficiency, including the roles of humoral and cellular immunity and genetics. The clinical manifestations, diagnosis, and treatment of adrenal insufficiency and its association with polyglandular autoimmune syndromes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H240131434">
         <span class="h1">
          AUTOIMMUNE PRIMARY ADRENAL INSUFFICIENCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune adrenalitis is characterized by the presence of serum antibodies against the steroidogenic enzymes P450scc (CYP11A1, side-chain cleavage enzyme), P450c17 (CYP17, 17-alpha-hydroxylase), and P450c21 (CYP21A2, 21-hydroxylase) [
         <a href="#rid1">
          1-3
         </a>
         ]. These enzymes are involved in the side-chain cleavage and subsequent hydroxylation of steroids  (
         <a class="graphic graphic_figure graphicRef71558" href="/z/d/graphic/71558.html" rel="external">
          figure 1
         </a>
         ). The autoantibodies to CYP21A2 are of the IgG1 or IgG2a subclass [
         <a href="#rid4">
          4,5
         </a>
         ], suggesting that T helper (Th) cells are involved in destruction of the adrenal cortex in patients with autoimmune Addison disease [
         <a href="#rid6">
          6
         </a>
         ]. Ample evidence demonstrates an important influence of genetic background on the development of adrenal insufficiency.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HUMORAL IMMUNITY
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Anti-adrenal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial studies evaluated the ability of serum antibodies to react with primate adrenal cortex using an indirect immunofluorescence technique. Because the test detects any IgG antibodies that are bound, it is not specific for a given antigen. Thus, the results are commonly referred to as "anti-adrenal" antibodies, reflecting the nonspecific nature of the test. Subsequent studies showed that the anti-adrenal autoantibodies detected by immunofluorescence on tissue sections were mainly directed against CYP17 and CYP21A2 [
         <a href="#rid7">
          7
         </a>
         ]. The clinical use of anti-adrenal antibodies is reviewed in more detail below and in a separate topic. (See
         <a class="local">
          'Prediction of adrenal insufficiency'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2688240919">
         <span class="h2">
          Polyglandular autoimmune syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune adrenalitis underlies most cases of isolated primary adrenal insufficiency in the developed world, as well as the adrenal insufficiency of polyglandular autoimmune syndrome type 1 (or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy [APECED]) and polyglandular autoimmune syndrome type 2. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'
         </a>
         .)
        </p>
        <p>
         Antibodies to all three zones of the adrenal cortex are present in the serum of 60 to 75 percent of patients with primary adrenal insufficiency caused by autoimmune adrenalitis; in contrast, they are rarely found in patients with other causes of adrenal insufficiency, in first-degree relatives of patients with autoimmune primary adrenal insufficiency, or in normal subjects [
         <a href="#rid1">
          1,8-13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Autoimmune adrenalitis'
         </a>
         .)
        </p>
        <p>
         The incidence of anti-adrenal antibodies in serum from patients with normal adrenal function who have other autoimmune endocrine diseases is low (2 percent), with the exception of those with hypoparathyroidism (16 percent)  (
         <a class="graphic graphic_table graphicRef70711" href="/z/d/graphic/70711.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid11">
          11,14-17
         </a>
         ]. In three reports comprising more than 2000 children and adults, 1 to 2 percent of patients with type 1 diabetes had antibodies against 21-hydroxylase (CYP21A2) [
         <a href="#rid18">
          18-20
         </a>
         ]. Given the low prevalence, routine screening of patients with type 1 diabetes for 21-hydroxylase antibodies is not indicated.
        </p>
        <p>
         Anti-adrenal antibodies are more common in women, particularly those with the polyglandular autoimmune syndrome type 2. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Prediction of adrenal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific tests for antibodies against the steroidogenic enzymes P450scc (CYP11A1, side-chain cleavage enzyme), P450c17 (CYP17, 17-alpha-hydroxylase), and p450c21 (CYP21A2, 21-hydroxylase) have been developed  (
         <a class="graphic graphic_figure graphicRef71558" href="/z/d/graphic/71558.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CYP21A2 autoantibodies are those most commonly detected in patients with APECED (13 to 14 of 15 patients) and sporadic disease (82 to 84 percent of 205 patients) based on a comparison of results from four laboratories [
         <a href="#rid21">
          21
         </a>
         ]. In that study, autoantibodies against CYP11A1 or CYP17 were detected in up to 50 percent of patients with polyglandular autoimmune disorders but less than 10 percent of those with sporadic disease. In a larger study of 52 Norwegian patients with APECED, 33 of 52 had autoimmune adrenal insufficiency. Of these, antibodies to CYP21A2 were most common (92 percent), followed by CYP11A1 (63 percent) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with antibodies develop adrenal insufficiency at a rate of up to 19 percent per year [
         <a href="#rid13">
          13,14,23
         </a>
         ]. In APECED syndrome, the presence of adrenal autoantibodies has a 92 percent predictive value for the development of adrenal insufficiency [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of 90 patients from Sweden, Norway, and Germany with type 1 polyglandular autoimmune syndrome, testing of CYP21A2 antibodies alone was sufficient for the prediction of adrenal insufficiency [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Younger age is associated with higher prevalence of antibodies and greater predictive value for development of adrenal insufficiency in APECED. One study evaluated 10 children with autoimmune hypoparathyroidism or diabetes mellitus who had adrenal cortex autoantibodies and antibodies to CYP21A2; nine developed adrenal insufficiency during 3 to 121 months of follow-up [
         <a href="#rid26">
          26
         </a>
         ]. In contrast, another report evaluated 48 adults with an autoimmune disorder and adrenal cortex autoantibodies (44 of whom had antibodies to CYP21A2); only 21 percent developed overt adrenal insufficiency and 29 percent subclinical adrenal insufficiency in four years [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The same investigators reported that of 100 patients with adrenal cortex autoantibodies, the estimated cumulative risk (using a life-table analysis) of developing overt adrenal insufficiency during a mean follow-up period of six years was 100 percent in children and 32 percent in adults [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Other antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against other organs and endocrine glands and cytokines are common in patients with autoimmune adrenal insufficiency (regardless of the cause) but rare in normal subjects  (
         <a class="graphic graphic_table graphicRef79074" href="/z/d/graphic/79074.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid8">
          8,10,11,15,29
         </a>
         ]. The presence of these antibodies correlates with clinical features.
        </p>
        <p>
         In patients with isolated autoimmune adrenal insufficiency and polyglandular autoimmune syndrome type 2 (see
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 2 (polygenic)'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 60 percent of patients have high serum antithyroid peroxidase (microsomal) antibody concentrations [
         <a href="#rid30">
          30
         </a>
         ], and almost one-half of these patients have overt hypothyroidism. Many other patients have subclinical hypothyroidism (ie, high serum thyroid-stimulating hormone [TSH] and normal serum thyroxine concentrations) and are at risk for developing overt hypothyroidism [
         <a href="#rid8">
          8,10,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of gastric parietal cell and intrinsic factor antibodies correlates with the presence of atrophic gastritis and pernicious anemia.
        </p>
        <p>
        </p>
        <p>
         In patients with polyglandular autoimmune syndrome type 1 (see
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 1 (monogenic)'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired hypoparathyroidism sometimes occurs in association with antiparathyroid gland antibodies that are directed against the calcium-sensing receptor in the parathyroid gland [
         <a href="#rid31">
          31
         </a>
         ] or against NACHT leucine-rich-repeat protein 5 (NALP5)/maternal antigen that embryo requires (MATER) [
         <a href="#rid22">
          22,32
         </a>
         ]. The latter is a parathyroid autoantigen also found in the ovary. (See
         <a class="medical medical_review" href="/z/d/html/840.html" rel="external">
          "Etiology of hypocalcemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoantibodies predicted gonadal failure (CYP11A1) and type 1 diabetes (tyrosine phosphatase-like protein IA-2) in a study of 90 patients [
         <a href="#rid25">
          25
         </a>
         ]. In a study of 68 Finnish patients, the presence of autoantibodies against the IA-2 tyrosine phosphatase-like protein or insulin had a 67 percent predictive value for type 1 diabetes [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucocutaneous candidiasis was associated with autoantibodies against interleukin (IL)-22 in 30 of 42 patients with this manifestation in the Norwegian study mentioned above [
         <a href="#rid22">
          22
         </a>
         ]. In the same study, autoantibodies against aromatic L-amino acid decarboxylase (AADC) were present in seven of eight patients with vitiligo. Anti-tryptophan hydroxylase antibodies were associated with both intestinal dysfunction and autoimmune hepatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-interferon autoantibodies, particularly to interferon omega and interferon alpha-2, are more common than the standard autoantibodies and correlate extremely well with mutated
         <em>
          AIRE
         </em>
         (autoimmune regulator), so they may be the diagnostic markers of choice, especially for early or atypical patients who have not developed the full polyglandular autoimmune syndrome type 1 picture [
         <a href="#rid22">
          22,25,33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CELLULAR IMMUNITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The autoantibodies to CYP21A2 in patients with isolated autoimmune adrenal insufficiency or autoimmune polyglandular syndromes type 1 or 2 are of the IgG1 or IgG2a subclass, implicating a type 1 T helper (Th1) cell response [
         <a href="#rid4">
          4,5
         </a>
         ]. The Th1 response is characterized by the production of interferon gamma, an antigen-specific, Th cell-driven process with cytotoxic T lymphocytes and activated macrophages mediating the destruction of the adrenal cortex. The presence of lymphocytic infiltration of the adrenal glands further supports a possible role for cellular immunity [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Decreased suppressor T-cell function [
         <a href="#rid36">
          36
         </a>
         ] and increased numbers of circulating Ia-positive T cells [
         <a href="#rid37">
          37
         </a>
         ] have been described in these patients. In addition, human adrenal homogenate inhibited the in vitro migration of leukocytes from 14 of 30 patients with idiopathic adrenal insufficiency, but only one of seven patients with tuberculous adrenal insufficiency [
         <a href="#rid38">
          38
         </a>
         ]. The substrate-binding domain of 21-hydroxylase is an immunodominant T cell epitope. Peripheral blood mononuclear cells (PBMCs) proliferate and secrete interferon gamma in the presence of CYP21A2 [
         <a href="#rid39">
          39
         </a>
         ] and PBMCs from patients with autoimmune adrenal insufficiency proliferate and increase interferon gamma secretion in the presence of CYP21A2 [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune adrenal insufficiency may be familial or nonfamilial. It is somewhat less likely to be familial when it occurs alone. Approximately one-third of such patients have affected family members, as compared with approximately one-half of patients who have adrenal insufficiency as part of polyglandular autoimmune syndrome type 1 or 2 [
         <a href="#rid41">
          41-44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 1 (monogenic)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 2 (polygenic)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          HLA associations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic susceptibility
         </strong>
         – The CYP21A1P (P450c21A) and CYP21A2 (P450c21B) genes are located in the human leukocyte antigen (HLA) class III region between the class I and class II loci on the short arm of chromosome 6 [
         <a href="#rid45">
          45
         </a>
         ]. This co-localization underlies the associations between certain HLA alleles and risk of autoimmune adrenal insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Genetic susceptibility to autoimmune adrenal insufficiency is strongly associated with HLA B8, DR3, and DR4 alleles, except when it occurs as part of polyglandular autoimmune syndrome type 1, in which no HLA association has been found [
         <a href="#rid43">
          43,46,47
         </a>
         ]. Several specific HLA class II antigens, including DQA1*0301, DQA1*0501, DQB1*0201, DQB1*0302, DRB1*0404, and DRB1*0301, are associated with sporadic autoimmune adrenal insufficiency and polyglandular autoimmune syndrome type 2 [
         <a href="#rid19">
          19,48-50
         </a>
         ]. These studies were carried out in individuals from Finland, Germany, and Italy, and race was not reported. Insufficient data are available to comment on HLA allele prevalence in Black, Asian, or Hispanic individuals with adrenal insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alterations in the HLA class I chain-related microsatellite also confer susceptibility. In a study of 28 patients with Addison disease and 75 healthy individuals in Italy, the combination of both the HLA class II DRB1*03-DQA1*0501-DQB1*0201 (DR3/DQ2) haplotype and the HLA class I chain-related microsatellite polymorphism MIC-A5.1 was necessary to confer increased genetic risk for Addison disease [
         <a href="#rid51">
          51
         </a>
         ]. Compared with individuals homozygous for MIC-A6, MIC-A5.1 homozygotes had a 60-fold greater risk of developing Addison disease. The normal function of the MIC-A gene product, which is expressed mostly in epithelial cells, is unknown, as is the role of the MIC-A5.1 allele in the pathogenesis of Addison disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         DQA1*0501 is associated with adrenal insufficiency, diabetes mellitus, and Graves' disease, and an Arg52 substitution in either DQA1*0501 or DQA1*0301 is also linked strongly with adrenal insufficiency [
         <a href="#rid49">
          49
         </a>
         ]. Patients with type 1 diabetes and a DRB1*0404/DQ8 genotype or the heterozygous DR3-DQ2/DR4B1*0404-DQ8 genotype who have circulating anti-CYP21A2 autoantibodies are at high risk for Addison disease, whereas those with DRB1*0401/DQ8 or DRB1*0402/DQ8 have much lower risk, despite having anti-CYP21A2 autoantibodies [
         <a href="#rid19">
          19,52
         </a>
         ]. No HLA linkage was evident in some families with polyglandular autoimmune syndrome type 2 [
         <a href="#rid46">
          46,53
         </a>
         ]. Furthermore, chronic autoimmune thyroiditis, pernicious anemia, and premature ovarian failure, all components of polyglandular autoimmune syndrome type 2, are not closely linked to any HLA haplotypes [
         <a href="#rid46">
          46,47
         </a>
         ]. These observations suggest that a gene or genes linked to certain HLA haplotypes confer susceptibility to autoimmune adrenal insufficiency and diabetes mellitus, but different, non-HLA-associated genes are linked to other autoimmune manifestations of polyglandular autoimmune syndrome type 2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protective factors
         </strong>
         – Conversely, certain HLA alleles may confer protection against development of adrenal insufficiency. In one study of 118 individuals with antibodies against CYP21A2 who were positive for the HLA DR4 allele, patients with confirmed adrenal insufficiency were much less likely to carry the HLA-B15 allele (1 of 55 [2 percent]) compared with those who did not have adrenal insufficiency (24 of 63 [40 percent]). On follow-up, none of those with HLA-B15 allele progressed to adrenal insufficiency, while 25 percent of those without the HLA-B15 did progress [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Presence of the DQB1*0602 allele appears to protect patients with polyglandular autoimmune syndrome type 1 from developing type 1 diabetes, as it does in the general population, but does not confer protective effects in patients with polyglandular autoimmune syndrome type 2 [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Non-HLA genes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causal and susceptibility genes
         </strong>
         – The gene responsible for polyglandular autoimmune syndrome type 1 is located on chromosome 21q22.3 [
         <a href="#rid55">
          55
         </a>
         ]. It is termed
         <em>
          AIRE
         </em>
         (autoimmune regulator) and encodes a protein that is probably a transcription factor [
         <a href="#rid56">
          56,57
         </a>
         ]. An Arg257 stop mutation was found in 10 of 12 Finnish patients with polyglandular autoimmune syndrome type 1, and a Lys83Glu mutation was found in Swiss and the remaining two Finnish patients [
         <a href="#rid56">
          56
         </a>
         ]. Eleven mutations were described in a nationwide study that identified 36 Norwegian patients [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Polymorphisms in the cytotoxic T lymphocyte antigen (CTLA)-4 gene (on chromosome 2q33), which have been reported to be associated with autoimmune thyroid disease, may also confer susceptibility to autoimmune adrenal insufficiency [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7841.html" rel="external">
          "Pathogenesis of Graves' disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A polymorphism in the class II transactivator (CIITA) gene, MHC2TA, is positively associated with genetic risk for autoimmune Addison disease, independently from HLA class II gene polymorphism [
         <a href="#rid50">
          50
         </a>
         ]. This gene regulates HLA-D gene expression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recent work implicates a number of other gene variants, many of which are involved in T-cell function, including CYP27B1, NLRP-1, PDL-1, STAT4, and GATA3 [
         <a href="#rid59">
          59-61
         </a>
         ]. A variant in t
         <em>
          he NFATC1
         </em>
         gene also may be associated with autoimmune adrenal insufficiency [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genes unlikely to contribute to susceptibility
         </strong>
         – The genes for CYP11A1 and CYP17, the targets for the anti-adrenal antibodies in most patients with autoimmune adrenal insufficiency, lie on chromosomes 15q23-q24 and 10q24-q25, respectively [
         <a href="#rid63">
          63
         </a>
         ]. These genes are therefore not linked to HLA haplotypes or implicated in the genetic susceptibility to autoimmune adrenalitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Normal adrenocortical cells express HLA class II molecules. Thus, inappropriate expression of these molecules is probably not involved in the pathogenesis of autoimmune adrenal insufficiency [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H801912073">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Humoral immunity
         </strong>
         – Autoimmune primary adrenal insufficiency is characterized by the presence of serum antibodies against the steroidogenic enzymes, most often P450c21 (CYP21A2, 21-hydroxylase) and less frequently P450scc (CYP11A1, side-chain cleavage enzyme) and P450c17 (CYP17, 17-alpha-hydroxylase). Ample evidence demonstrates an important influence of genetic background on the development of adrenal insufficiency  (
         <a class="graphic graphic_figure graphicRef71558" href="/z/d/graphic/71558.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Autoimmune primary adrenal insufficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-adrenal antibodies
         </strong>
         – Anti-adrenal antibodies are more common in women, particularly those with the polyglandular autoimmune syndrome (type 2). Patients with antibodies develop adrenal insufficiency at a rate of up to 19 percent per year. In autoimmune polyendocrinopathy syndrome type 1 (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy [APECED] syndrome), the presence of adrenal autoantibodies has a 92 percent predictive value for the development of adrenal insufficiency. (See
         <a class="local">
          'Anti-adrenal antibodies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other antibodies
         </strong>
         – Antibodies against other endocrine glands are common in patients with autoimmune adrenal insufficiency but rare in healthy individuals. Polyglandular autoimmune syndromes are discussed separately. (See
         <a class="local">
          'Other antibodies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic susceptibility
         </strong>
         – Autoimmune adrenal insufficiency may be familial or nonfamilial. It is somewhat less likely to be familial when it occurs alone. Approximately one-third of such patients have affected family members, as compared with approximately one-half of patients who have adrenal insufficiency as part of polyglandular autoimmune syndrome type 1 or 2. (See
         <a class="local">
          'Genetics'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 1 (monogenic)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 2 (polygenic)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          HLA associations
         </strong>
         – Genetic susceptibility to autoimmune adrenal insufficiency is strongly associated with human leukocyte antigen (HLA) B8, DR3, and DR4 alleles, except when it occurs as part of polyglandular autoimmune syndrome type 1, in which no HLA association has been found. (See
         <a class="local">
          'HLA associations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-HLA genes
         </strong>
         – The gene responsible for polyglandular autoimmune syndrome type 1 is located on chromosome 21q22.3. It is termed
         <em>
          AIRE
         </em>
         (autoimmune regulator) and encodes a protein that is probably a transcription factor. However, the genes for CYP11A1 and CYP17, the other two targets for the anti-adrenal antibodies in patients with autoimmune adrenal insufficiency, lie on chromosomes 15q23-q24 and 10q24-q25, respectively. These genes are therefore
         <strong>
          not
         </strong>
         linked to HLA haplotypes or implicated in the genetic susceptibility to autoimmune adrenalitis. (See
         <a class="local">
          'Non-HLA genes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1060437899">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nerup J. Addison's disease--serological studies. Acta Endocrinol (Copenh) 1974; 76:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boscaro M, Betterle C, Sonino N, et al. Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. J Clin Endocrinol Metab 1994; 79:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song YH, Connor EL, Muir A, et al. Autoantibody epitope mapping of the 21-hydroxylase antigen in autoimmune Addison's disease. J Clin Endocrinol Metab 1994; 78:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen S, Sawicka J, Prentice L, et al. Analysis of autoantibody epitopes on steroid 21-hydroxylase using a panel of monoclonal antibodies. J Clin Endocrinol Metab 1998; 83:2977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brozzetti A, Marzotti S, La Torre D, et al. Autoantibody responses in autoimmune ovarian insufficiency and in Addison's disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of response. Eur J Endocrinol 2010; 163:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bøe AS, Bredholt G, Knappskog PM, et al. Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1. Eur J Endocrinol 2004; 150:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blizzard RM, Chee D, Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irvine, WJ, Barnes, EW. Addison's disease, ovarian failure and hypoparathyroidism. Clin Endocrinol Metab 1975; 4:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irvine WJ, Stewart AG, Scarth L. A clinical and immunological study of adrenocortical insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irvine WJ, Barnes EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colls J, Betterle C, Volpato M, et al. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin Chem 1995; 41:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falorni A, Nikoshkov A, Laureti S, et al. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 1995; 80:2752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988; 117:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blizzard RM, Chee D, Davis W. The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism. Clin Exp Immunol 1966; 1:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketchum CH, Riley WJ, Maclaren NK. Adrenal dysfunction in asymptomatic patients with adrenocortical autoantibodies. J Clin Endocrinol Metab 1984; 58:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherbaum WA, Berg PA. Development of adrenocortical failure in non-Addisonian patients with antibodies to adrenal cortex. A clinical follow-up study. Clin Endocrinol (Oxf) 1982; 16:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brewer, KW, Parziale, et al. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency (letter). New Engl J Med 1997; 337:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triolo TM, Armstrong TK, McFann K, et al. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 2011; 34:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falorni A, Chen S, Zanchetta R, et al. Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol 2011; 140:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruserud Ø, Oftedal BE, Landegren N, et al. A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab 2016; 101:2975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gylling M, Tuomi T, Björses P, et al. ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000; 85:4434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Söderbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Volpato M, Rees Smith B, et al. II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Volpato M, Rees Smith B, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coco G, Dal Pra C, Presotto F, et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006; 91:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid antibody studies in Addison's disease. Clin Endocrinol (Oxf) 1972; 1:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun 1995; 8:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 1996; 97:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brozzetti A, Alimohammadi M, Morelli S, et al. Autoantibody response against NALP5/MATER in primary ovarian insufficiency and in autoimmune Addison's disease. J Clin Endocrinol Metab 2015; 100:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007; 92:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolff AS, Sarkadi AK, Maródi L, et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol 2013; 33:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neville, AM, Mackay, AM. The structure of the human adrenal cortex in health and disease. Clin Endocrinol Metab 1972; 1:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairchild RS, Schimke RN, Abdou NI. Immunoregulation abnormalities in familial Addison's disease. J Clin Endocrinol Metab 1980; 51:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabinowe SL, Jackson RA, Dluhy RG, Williams GH. Ia-positive T lymphocytes in recently diagnosed idiopathic Addison's disease. Am J Med 1984; 77:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nerup J, Bendixen G. Anti-adrenal cellular hypersensitivity in Addison's disease. II. Correlation with clinical and serological findings. Clin Exp Immunol 1969; 5:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husebye ES, Bratland E, Bredholt G, et al. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology 2006; 147:2411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratland E, Skinningsrud B, Undlien DE, et al. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009; 94:5117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci 1985; 290:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinner MW, Blizzard RM, Childs B. Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol Metab 1968; 28:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988; 9:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farid NR, Bear JC. The human major histocompatibility complex and endocrine disease. Endocr Rev 1981; 2:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maclaren NK, Riley WJ. Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus. Diabetes Care 1985; 8 Suppl 1:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partanen J, Peterson P, Westman P, et al. Major histocompatibility complex class II and III in Addison's disease. MHC alleles do not predict autoantibody specificity and 21-hydroxylase gene polymorphism has no independent role in disease susceptibility. Hum Immunol 1994; 41:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badenhoop K, Walfish PG, Rau H, et al. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 1995; 80:2112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghaderi M, Gambelunghe G, Tortoioli C, et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J Clin Endocrinol Metab 2006; 91:4107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambelunghe G, Falorni A, Ghaderi M, et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J Clin Endocrinol Metab 1999; 84:3701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myhre AG, Undlien DE, Løvås K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler MG, Hodes ME, Conneally PM, et al. Linkage analysis in a large kindred with autosomal dominant transmission of polyglandular autoimmune disease type II (Schmidt syndrome). Am J Med Genet 1984; 18:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker PR, Baschal EE, Fain PR, et al. Dominant suppression of Addison's disease associated with HLA-B15. J Clin Endocrinol Metab 2011; 96:2154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aaltonen J, Björses P, Sandkuijl L, et al. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994; 8:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomhoff A, Lie BA, Myhre AG, et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J Clin Endocrinol Metab 2004; 89:3474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson D, Bianchi M, Landegren N, et al. Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison's disease. J Intern Med 2016; 280:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell AL, Macarthur KD, Gan EH, et al. Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European cohorts. PLoS One 2014; 9:e88991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell AL, Cordell HJ, Soemedi R, et al. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility. J Clin Endocrinol Metab 2009; 94:5139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell AL, Bøe Wolff A, MacArthur K, et al. Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus. PLoS One 2015; 10:e0123550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparkes RS, Klisak I, Miller WL. Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25. DNA Cell Biol 1991; 10:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson R, McNicol AM, Farquharson M, Foulis AK. Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison's disease. J Pathol 1988; 155:113.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 169 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4208440" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Addison's disease--serological studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8045962" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7513715" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Autoantibody epitope mapping of the 21-hydroxylase antigen in autoimmune Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709979" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Analysis of autoantibody epitopes on steroid 21-hydroxylase using a panel of monoclonal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20498138" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Autoantibody responses in autoimmune ovarian insufficiency and in Addison's disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14713279" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8626850" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6030795" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Addison's disease, ovarian failure and hypoparathyroidism
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5340030" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A clinical and immunological study of adrenocortical insufficiency (Addison's disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Adrenocortical insufficiency
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7882511" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7673419" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3392502" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The natural history of adrenal function in autoimmune patients with adrenal autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5330781" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6725513" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Adrenal dysfunction in asymptomatic patients with adrenocortical autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6896476" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Development of adrenocortical failure in non-Addisonian patients with antibodies to adrenal cortex. A clinical follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9221352" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920103" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21430083" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Additional autoimmune disease found in 33% of patients at type 1 diabetes onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21570358" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27253668" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3818889" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134089" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14764761" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9062510" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9062509" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16522688" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4664289" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Serum TSH and thyroid antibody studies in Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7734032" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Associated autoimmunity in Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8613543" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25734249" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Autoantibody response against NALP5/MATER in primary ovarian insufficiency and in autoimmune Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17118990" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24158785" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The structure of the human adrenal cortex in health and disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6448266" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Immunoregulation abnormalities in familial Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6333179" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ia-positive T lymphocytes in recently diagnosed idiopathic Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4902501" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Anti-adrenal cellular hypersensitivity in Addison's disease. II. Correlation with clinical and serological findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16497795" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19890026" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3898841" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Polyglandular autoimmune syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4406578" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Addison's disease--clinical studies. A report fo 108 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7024719" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5656437" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3061784" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Molecular biology of steroid hormone synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7028471" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The human major histocompatibility complex and endocrine disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4053951" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7860358" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Major histocompatibility complex class II and III in Addison's disease. MHC alleles do not predict autoantibody specificity and 21-hydroxylase gene polymorphism has no independent role in disease susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7608264" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16849401" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10523017" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836294" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6588752" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Linkage analysis in a large kindred with autosomal dominant transmission of polyglandular autoimmune disease type II (Schmidt syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21565792" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Dominant suppression of Addison's disease associated with HLA-B15.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7987397" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9398839" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Positional cloning of the APECED gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9398840" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15240634" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27807919" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24614117" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850680" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042420" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863359" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3292733" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison's disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
